Investigation of the Opposite Capacities of Erythropoietin and U-74389G on Platelet Crit Levels

Abstract

Aim: This study calculated the opposite capacities of 2 drugs: the erythropoietin (Epo) and the antioxidant drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the platelet crit (PCT) levels alterations, after the respective drug usage in an induced hypoxia reoxygenation animal experiment. Materials and methods:The 2 main experimental endpoints at which the PCT levels (PCTl) were evaluated were the 60th reoxygenation min (for the groups A, C and E) and the 120th reoxygenation min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after U-74389G administration. Results:The first preliminary study of Epo non significantly decreased the PCTl by 6.88% ± 3.69% (p-value=0.0615). Also, the second preliminary study of U-74389G non-significantly increased the PCTl by 6.73% ± 37.45% (p-value=0.0712). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has opposite acute effect than Epo (p-value=0.0000). Conclusion:The anti-oxidant capacities of U-74389G enhance the acute increasing properties on PCTl than epo (p-value=0.0000).

Comparison of the Acute Erythropoietic Capacities of Erythropoietin and U-74389G Concerning Red Blood Cells Counts

“…Examined the effect of intraperitoneal injections of 40 mg/kg of the lazaroid compound U-74389G every 12 hours, on acute otitis media in guinea pigs. Streptococcus pneumoniae organisms were inoculated into the right tympanic cavity; with the left ear served as a control [32].…”

“…A U-74389G/ erythropoietin efficacies ratios meta-analysis on 5 hematologic variables (3 variables with balancing efficacies and 2 variables with opposite efficacies)[32].…”